<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">surgonco</journal-id><journal-title-group><journal-title xml:lang="ru">Креативная хирургия и онкология</journal-title><trans-title-group xml:lang="en"><trans-title>Creative surgery and oncology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2076-3093</issn><issn pub-type="epub">2307-0501</issn><publisher><publisher-name>Башкирский государственный медицинский университет</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24060/2076-3093-2023-13-2-165-170</article-id><article-id custom-type="elpub" pub-id-type="custom">surgonco-814</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЙ СЛУЧАЙ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL CASES</subject></subj-group></article-categories><title-group><article-title>Методы экстракорпоральной детоксикации и система гемостаза пациентов с раком яичников. Клинический случай</article-title><trans-title-group xml:lang="en"><trans-title>Extracorporeal Detoxification Methods and Hemostasis System for Ovarian Cancer Patients. Clinical Case</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5398-5585</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сафонов</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Safonov</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Антон Сергеевич Сафонов, к. м. н.</p><p>ИДПО</p><p>кафедра хирургии с курсом эндоскопии</p><p>Республика Башкортостан</p><p>Уфа</p></bio><bio xml:lang="en"><p>Anton S. Safonov, Cand. Sci. (Med.)</p><p>Department of Surgery with a Course of Endoscopy for Advanced Professional Education</p><p>Ufa</p></bio><email xlink:type="simple">antoniosaf-88@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9816-3614</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Забелин</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zabelin</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Максим Васильевич Забелин, д. м. н., профессор</p><p>ИДПО</p><p>кафедра хирургии с курсом эндоскопии</p><p>Республика Башкортостан</p><p>Уфа</p></bio><bio xml:lang="en"><p>Maksim V. Zabelin,  Dr. Sci. (Med.), Prof.</p><p>Department of Surgery with a Course of Endoscopy for Advanced Professional Education</p><p>Ufa</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8461-9243</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Измайлов</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Izmailov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Адель Альбертович Измайлов, д. м. н., доцент</p><p>кафедра урологии с курсом ИДПО</p><p>Республика Башкортостан</p><p>Уфа</p></bio><bio xml:lang="en"><p>Adel A. Izmailov,  Dr. Sci. (Med.), Assoc. Prof.</p><p>Department of Urology with a Сourse of Advanced Professional Education</p><p>Ufa</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-9107-0435</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Валиуллина</surname><given-names>З. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Valiullina</surname><given-names>Z. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Зульфия Альбертовна Валиуллина</p><p>кафедра фармакологии с курсом клинической фармакологии</p><p>Республика Башкортостан</p><p>Уфа</p></bio><bio xml:lang="en"><p>Zulfiya A. Valiullina, Department of Pharmacology with a Course of ClinicalPharmacology</p><p>Ufa</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мухаметкулова</surname><given-names>А. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Mukhametkulova</surname><given-names>A. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Альбина Рифовна Мухаметкулова</p><p>кафедра фармакологии с курсом клинической фармакологии</p><p>Республика Башкортостан</p><p>Уфа</p></bio><bio xml:lang="en"><p>Albina R. Mukhametkulova</p><p>Department of Pharmacology with a Course of Clinical Pharmacology</p><p>Ufa</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Васильченко</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vasilchenko</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Андрей Владимирович Васильченко, к. м. н.</p><p>кафедра криминалистики</p><p>Республика Башкортостан</p><p>Уфа</p></bio><bio xml:lang="en"><p>Andrey V. Vasilchenko, Cand. Sci. (Med.)</p><p>Department of Forensics</p><p>Ufa</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Золотухин</surname><given-names>К. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Zolotukhin</surname><given-names>K. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Константин Николаевич Золотухин, к. м. н.</p><p>кафедра анестезиологии и реаниматологии</p><p>Республика Башкортостан</p><p>Уфа</p></bio><bio xml:lang="en"><p>Konstantin N. Zolotukhin, Cand. Sci. (Med.)</p><p>Department of Anesthesiology and Resuscitation</p><p>Ufa</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Башкирский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Bashkir State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Уфимский юридический институт МВД России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ufa Law Institute of the Ministry of Internal Aff airs of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>01</day><month>07</month><year>2023</year></pub-date><volume>13</volume><issue>2</issue><fpage>165</fpage><lpage>170</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Сафонов А.С., Забелин М.В., Измайлов А.А., Валиуллина З.А., Мухаметкулова А.Р., Васильченко А.В., Золотухин К.Н., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Сафонов А.С., Забелин М.В., Измайлов А.А., Валиуллина З.А., Мухаметкулова А.Р., Васильченко А.В., Золотухин К.Н.</copyright-holder><copyright-holder xml:lang="en">Safonov A.S., Zabelin M.V., Izmailov A.A., Valiullina Z.A., Mukhametkulova A.R., Vasilchenko A.V., Zolotukhin K.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.surgonco.ru/jour/article/view/814">https://www.surgonco.ru/jour/article/view/814</self-uri><abstract><sec><title>   Введение</title><p>   Введение. Злокачественные новообразования занимают лидирующую позицию в общей структуре инвалидности и смертности во всем мире. Одним из наиболее частых и грозных сопутствующих состояний является повреждение почек. При этом наиболее неблагоприятная частота развития острого повреждения почек регистрируется при множественной миеломе, лейкемии, лимфоме и раке почки и / или печени и злокачественных новообразованиях яичников. В связи с этим жизненно важным становится выбор тактики при профилактике тромбозов и тромбоэмболических осложнений, а также обеспечение индивидуального подбора режима антикоагулянтной терапии при сеансах почечно-заместительной терапии в зависимости от основного заболевания и состояния системы гемостаза.</p><p>   Целью демонстрации данного клинического случая является оценка влияния сеансов кальций-цитратной вено-венозной гемодиафильтрации на показатели системы гемостаза пациентки с прогрессированием органных дисфункций, развившихся на фоне злокачественного новообразования яичников.</p></sec><sec><title>   Материалы и методы</title><p>   Материалы и методы. Анализ доступной литературы и представленного клинического случая для оценки влияния вено-венозной гемодиафильтрации на показатели системы гемостаза.</p><p>   Результаты и обсуждение. В приведенном клиническом случае мы оценили экспрессию P-селектина (CD62), который характеризует процессы активации тромбоцитов. Следует отметить, что у данной пациентки с каждым сеансом заместительной почечной терапии возрастала экспрессия Р-селектина, при этом значения агрегации тромбоцитов оставались на уровне нижних пороговых показателей, что свидетельствует о низкой вероятности инициации свертывания крови. Однако, принимая во внимание факт агрессивного регулирования рака яичника системой гемостаза в виде продукции медиаторов воспаления, микровезикул, экспрессии тканевого фактора и активации эндотелия, следует обратить внимание на молекулярные аспекты активации тромбоцитов при почечно-заместительной терапии с регионарной цитратной коагуляцией.</p></sec><sec><title>   Выводы</title><p>   Выводы. Таким образом, широкое распространение методов экстракорпоральной детоксикации является самостоятельным фактором риска не только развития кровотечений, но может и потенциально способствовать развитию тромбозов и тромбоэмболических осложнений, что требует детального дальнейшего изучения молекулярных механизмов регулирования системы гемостаза опухолью и клинической оценкой различных методов антикоагуляции.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>   Introduction</title><p>   Introduction. Malignant tumors dominate in the picture of disability and mortality worldwide. One of the most frequent and dangerous comorbid conditions is kidney injury. At the same time, the most unfavorable incidence of acute kidney injury is recorded in multiple myeloma, leukemia, lymphoma and kidney and/or liver cancer and malignant ovarian neoplasms. In this regard, of vital importance is the choice of tactics in the prevention of thrombosis and thromboembolic complications, as well as the individual approach to of the anticoagulant therapy regimen during renal replacement therapy sessions, depending on the underlying disease and the state of the hemostatic system.</p></sec><sec><title>   Aim</title><p>   Aim. To evaluate the effect of calcium citrate veno-venous hemodiafi ltration sessions on the hemostatic system of a patient with progressive organ dysfunctions associated with malignant ovarian neoplasm.</p></sec><sec><title>   Materials and methods</title><p>   Materials and methods. The methodology involved literature review and a case study to assess the effect of veno-venous hemodiafi ltration on hemostasis.</p><p>   Results and discussion. The clinical case was assessed in terms of P-selectin (CD62), which characterizes platelet activation processes. It should be noted that in this patient, the expression of P-selectin increased with each session of renal replacement therapy, while the platelet aggregation values remained at the level of the lower thresholds, which indicates a low probability of coagulation initiation. However, due to aggressive regulation of ovarian cancer by the hemostatic system in the form of production of inflammatory mediators, microvesicles, tissue factor expression and endothelial activation, attention should be paid to the molecular aspects of platelet activation in renal replacement therapy with regional citrate coagulation.</p></sec><sec><title>   Conclusion</title><p>   Conclusion. The widespread use of extracorporeal detoxification methods is an independent risk factor not only for bleeding events, but may potentially contribute to thrombosis and thromboembolic complications, which requires a further detailed study of molecular mechanisms of hemostasis regulation by tumor and clinical evaluation of various anticoagulation methods.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>злокачественные новообразования яичников</kwd><kwd>система гемостаза</kwd><kwd>экспрессия Р-селектина</kwd><kwd>почечно-заместительная терапия</kwd><kwd>гемодиализ</kwd><kwd>почечная недостаточность</kwd><kwd>факторы риска</kwd></kwd-group><kwd-group xml:lang="en"><kwd>ovarian malignancies</kwd><kwd>hemostatic system</kwd><kwd>P-selectin expression</kwd><kwd>renal replacement therapy</kwd><kwd>hemodialysis</kwd><kwd>renal failure</kwd><kwd>risk factors</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Данная работа не финансировалась</funding-statement><funding-statement xml:lang="en">This work is not funded</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Global Burden of Disease Study Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392 (10159): 1736–88. DOI: 10.1016/S0140-6736(18)32203-7</mixed-citation><mixed-citation xml:lang="en">Global Burden of Disease Study Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392 (10159): 1736–88. DOI: 10.1016/S0140-6736(18)32203-7</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396 (10258): 1204–22. DOI: 10.1016/S0140-6736(20)30925-9</mixed-citation><mixed-citation xml:lang="en">GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396 (10258): 1204–22. DOI: 10.1016/S0140-6736(20)30925-9</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Santucci C., Carioli G., Bertuccio P., Malvezzi M., Pastorino U., Boffetta P., et al. Progress in cancer mortality, incidence, and survival: a global overview. Eur J Cancer Prev. 2020;29 (5): 367–81. DOI: 10.1097/CEJ.0000000000000594</mixed-citation><mixed-citation xml:lang="en">Santucci C., Carioli G., Bertuccio P., Malvezzi M., Pastorino U., Boffetta P., et al. Progress in cancer mortality, incidence, and survival: a global overview. Eur J Cancer Prev. 2020;29 (5): 367–81. DOI: 10.1097/CEJ.0000000000000594</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Xie X., Li F., Xie L., Yu Y., Ou S., He R. Meta-analysis of cancer risk among end stage renal disease undergoing maintenance dialysis. Open Life Sci. 2023; 18 (1): 20220553. DOI: 10.1515/biol-2022-0553</mixed-citation><mixed-citation xml:lang="en">Xie X., Li F., Xie L., Yu Y., Ou S., He R. Meta-analysis of cancer risk among end stage renal disease undergoing maintenance dialysis. Open Life Sci. 2023; 18 (1): 20220553. DOI: 10.1515/biol-2022-0553</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Miyamoto Y., Iwagami M., Aso S., Uda K., Fushimi K., Hamasaki Y., et al. Postoperative outcomes of cancer surgery in patients with and without kidney failure with dialysis therapy: a matched-pair cohort study. Clin Kidney J. 2022; 15 (6): 1137–43. DOI: 10.1093/ckj/sfac005</mixed-citation><mixed-citation xml:lang="en">Miyamoto Y., Iwagami M., Aso S., Uda K., Fushimi K., Hamasaki Y., et al. Postoperative outcomes of cancer surgery in patients with and without kidney failure with dialysis therapy: a matched-pair cohort study. Clin Kidney J. 2022; 15 (6): 1137–43. DOI: 10.1093/ckj/sfac005</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Wong G., Staplin N., Emberson J., Baigent C., Turner R., Chalmers J., et al. Chronic kidney disease and the risk of cancer: an individual patient data meta-analysis of 32,057 participants from six prospective studies. BMC Cancer. 2016;16:488. DOI: 10.1186/s12885-016-2532-6</mixed-citation><mixed-citation xml:lang="en">Wong G., Staplin N., Emberson J., Baigent C., Turner R., Chalmers J., et al. Chronic kidney disease and the risk of cancer: an individual patient data meta-analysis of 32,057 participants from six prospective studies. BMC Cancer. 2016;16:488. DOI: 10.1186/s12885-016-2532-6</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Хайбуллина Р. Р., Данилко К. В., Шангина О. Р., Валеева Г. А., Лопатина Н. В., Герасимова Л. П. Способ лечения пародонтита с помощью мультипотентных мезенхимальных стволовых клеток пульпы зуба человека и препарата стимулятора остеогенеза : патент Российской Федерации № 2785009 от 01. 12. 2022.</mixed-citation><mixed-citation xml:lang="en">Khajbullina R. R., Danilko K. V., Shangina O. R., Valeeva G. A., Lopatina N. V., Gerasimova L. P. Method for treating periodontitis using multipotent mesenchymal stem cells of human tooth pulp and an osteogenesis stimulator agent: Russian Federation patent 2785009 2022 December 01. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Хайбуллина Р. Р., Данилко К. В., Шангина О. Р., Валеева Г. А., Лопатина Н. В., Галиахметова И. А., Герасимова Л. П., Кабирова М. Ф. Способ лечения пародонтита с использованием смеси микса мягких и твердых частиц элитных семян крамбе сорта санмо и фитоконцентрата санмо : патент Российской Федерации № 2785008 от 01. 12. 2022.</mixed-citation><mixed-citation xml:lang="en">Khajbullina R. R., Danilko K. V., Shangina O. R., Valeeva G. A., Lopatina N. V., Galiakhmetova I. A., Gerasimova L. P., Kabirova M. F. Method for treating periodontitis using a mix of soft and hard particles of elite seeds of crambe of sanmo variety and sanmo phytoconcentrate: Russian Federation patent 2785008 2022 December 01. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Хайбуллина Р. Р., Данилко К. В., Шангина О. Р., Лопатина Н. В., Валеева Г. А., Галиахметова И. А., Герасимова Л. П., Кабирова М. Ф. Способ лечения рецессии десны с использованием мультипотентных мезенхимальных стволовых клеток : патент Российской Федерации № 2785189 от 05. 12. 2022.</mixed-citation><mixed-citation xml:lang="en">Khajbullina R. R., Danilko K. V., Shangina O. R., Lopatina N. V., Valeeva G. A., Galiakhmetova I. A., Gerasimova L. P., Kabirova M. F. Method for treating gum recession using multipotent mesenchymal stem cells: Russian Federation patent 2785189 2022 December 05. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Хайбуллина Р. Р., Данилко К. В., Лопатина Н. В., Галиахметова И. А., Герасимова Л. П., Кабирова М. Ф. Способ лечения рецессии десны с использованием масла SANS MOTS : патент Российской Федерации № 2787679 от 11. 01. 2023.</mixed-citation><mixed-citation xml:lang="en">Khajbullina R. R., Danilko K. V., Lopatina N. V., Galiakhmetova I. A., Gerasimova L. P., Kabirova M. F. Method for treatment of gingi recession using SANS MOTS oil: Russian Federation patent 2787679 2023 January 11. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Хайбуллина Р. Р., Данилко К. В., Лопатина Н. В., Герасимова Л. П. Способ моделирования рецессии десны : патент Российской Федераци № 2791563 от 10. 03. 2023.</mixed-citation><mixed-citation xml:lang="en">Khajbullina R. R., Danilko K. V., Lopatina N. V., Gerasimova L. P. Method for modeling gum recession: Russian Federation patent 2791563 2023 Marth. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Jorgensen L., Heuch I., Jenssen T., Jacobsen B. K. Association of albuminuria and cancer incidence. J Am Soc Nephrol. 2008; 19 (5): 992–8. DOI: 10.1681/ASN.2007060712</mixed-citation><mixed-citation xml:lang="en">Jorgensen L., Heuch I., Jenssen T., Jacobsen B. K. Association of albuminuria and cancer incidence. J Am Soc Nephrol. 2008; 19 (5): 992–8. DOI: 10.1681/ASN.2007060712</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Habas E., Akbar R., Farfar K., Arrayes N., Habas A., Rayani A., et al. Malignancy diseases and kidneys: A nephrologist prospect and updated review. Medicine (Baltimore). 2023; 102 (15): e33505. DOI: 10.1097/MD.0000000000033505</mixed-citation><mixed-citation xml:lang="en">Habas E., Akbar R., Farfar K., Arrayes N., Habas A., Rayani A., et al. Malignancy diseases and kidneys: A nephrologist prospect and updated review. Medicine (Baltimore). 2023; 102 (15): e33505. DOI: 10.1097/MD.0000000000033505</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Lowrance W. T., Ordonez J., Udaltsova N., Russo P., Go A. S. CKD and the risk of incident cancer. J Am Soc Nephrol. 2014; 25 (10): 2327–34. DOI: 10.1681/ASN.2013060604</mixed-citation><mixed-citation xml:lang="en">Lowrance W. T., Ordonez J., Udaltsova N., Russo P., Go A. S. CKD and the risk of incident cancer. J Am Soc Nephrol. 2014; 25 (10): 2327–34. DOI: 10.1681/ASN.2013060604</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Chinnadurai R., Flanagan E., Jayson G. C., Kalra P. A. Cancer patterns and association with mortality and renal outcomes in non-dialysis dependent chronic kidney disease: a matched cohort study. BMC Nephrol. 2019; 20 (1): 380. DOI: 10.1186/s12882-019-1578-5</mixed-citation><mixed-citation xml:lang="en">Chinnadurai R., Flanagan E., Jayson G. C., Kalra P. A. Cancer patterns and association with mortality and renal outcomes in non-dialysis dependent chronic kidney disease: a matched cohort study. BMC Nephrol. 2019; 20 (1): 380. DOI: 10.1186/s12882-019-1578-5</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Swier N., Versteeg H. H. Reciprocal links between venous thromboembolism, coagulation factors and ovarian cancer progression. Th rombosis Research. 2017; 150: 8–18. DOI: 10.1016/j.thromres.2016.12.002</mixed-citation><mixed-citation xml:lang="en">Swier N., Versteeg H. H. Reciprocal links between venous thromboembolism, coagulation factors and ovarian cancer progression. Th rombosis Research. 2017; 150: 8–18. DOI: 10.1016/j.thromres.2016.12.002</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Brandenburger T., Dimski T., Slowinski T., Kindgen-Milles D. Renal replacement therapy and anticoagulation. Best Pract Res Clin Anaesthesiol. 2017; 31 (3): 387–401. DOI: 10.1016/j.bpa.2017.08.005</mixed-citation><mixed-citation xml:lang="en">Brandenburger T., Dimski T., Slowinski T., Kindgen-Milles D. Renal replacement therapy and anticoagulation. Best Pract Res Clin Anaesthesiol. 2017; 31 (3): 387–401. DOI: 10.1016/j.bpa.2017.08.005</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Fisher R., Moore G. W., Mitchell M. J., Dai L., Crichton S., Lumlertgul N., et al. Effects of regional citrate anticoagulation on thrombin generation, fibrinolysis and platelet function in critically ill patients receiving continuous renal replacement therapy for acute kidney injury: a prospective study. Ann Intensive Care. 2022; 12 (1): 29. DOI: 10.1186/s13613-022-01004-w</mixed-citation><mixed-citation xml:lang="en">Fisher R., Moore G. W., Mitchell M. J., Dai L., Crichton S., Lumlertgul N., et al. Effects of regional citrate anticoagulation on thrombin generation, fibrinolysis and platelet function in critically ill patients receiving continuous renal replacement therapy for acute kidney injury: a prospective study. Ann Intensive Care. 2022; 12 (1): 29. DOI: 10.1186/s13613-022-01004-w</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Z. Y., Feng S. H., Fan B. L., Ma W., Jia X. C., Geng H. Effects of regional citrate anticoagulation in continuous veno-venous hemofi ltration of severe burn patients. Zhonghua Shao Shang Za Zhi. 2021; 37 (12): 1137–42. Chinese. DOI: 10.3760/cma.j.cn501120-20200816-00381</mixed-citation><mixed-citation xml:lang="en">Wang Z. Y., Feng S. H., Fan B. L., Ma W., Jia X. C., Geng H. Effects of regional citrate anticoagulation in continuous veno-venous hemofi ltration of severe burn patients. Zhonghua Shao Shang Za Zhi. 2021; 37 (12): 1137–42. Chinese. DOI: 10.3760/cma.j.cn501120-20200816-00381</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang C., Lin T., Zhang J., Liang H., Di Y., Li N., et al. Safety and efficacy of regional citrate anticoagulation in continuous renal replacement therapy in the presence of acute kidney injury aft er hepatectomy. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2018; 30 (8): 777–82. Chinese. DOI: 10.3760/cma.j.issn.2095-4352.2018.08.013</mixed-citation><mixed-citation xml:lang="en">Zhang C., Lin T., Zhang J., Liang H., Di Y., Li N., et al. Safety and efficacy of regional citrate anticoagulation in continuous renal replacement therapy in the presence of acute kidney injury aft er hepatectomy. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2018; 30 (8): 777–82. Chinese. DOI: 10.3760/cma.j.issn.2095-4352.2018.08.013</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
